Soooo... I can only assume that any money to be made back would have to come through the drug having a descent life.
Hardly the enormous revenues that Axiron had pouring in - back in the day.
So have we been sold a pup here about these drugs? Is this whole dog and pony show little more than a ruse to keep the wheels turning for a few more years? Their presentations seemed to indicate that their is a descent market segment which we could get a descent share of.
Ann: Acrux receives third FDA ANDA approval, page-10
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
